Single agent lenalidomide induces a response in refractory T-cell posttransplantation lymphoproliferative disorder.

inhibition of T-cells by dasatinib is achievable in murine models, but the doses required were higher than those required to inhibit CML models.9 Thus, if the in vivo effects of dasatinib against NK cells are similar to those against T-cells, once-daily dosing with dasatinib may result in only minor suppression of NK cell function and greater suppression might occur when dasatinib is taken at higher doses or with greater frequency. Further in vivo studies expanding on our findings will assist in discerning any effects of dasatinib on NK cell function in patients.